Arnold Library

Second Generation Tyrosine Kinase Inhibitor Effective In First Line CML Therapy

Morris, Valerie (2012) Second Generation Tyrosine Kinase Inhibitor Effective In First Line CML Therapy. Science Spotlight, 2 (10).

[img]
Preview
Text
Second Generation Tyrosine Kinase Inhibitor Effective In First Line CML Therapy.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (352Kb) | Preview
Article URL: http://www.bloodjournal.org/content/120/19/3898
Item Type: Article
Additional Information: Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Druker BJ. 2012. A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chromic myeloid leukemia. Blood. Epub ahead of print, doi: 10.1182/blood-2012-02-410688.
Collections: Science Spotlight
Depositing User: Ben Abraham
Date Deposited: 20 Mar 2015 21:53
Last Modified: 20 Mar 2015 21:53
URI: http://authors.fhcrc.org/id/eprint/896

Repository Administrators Only

View Item View Item
Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N. PO Box 19024
Seattle, WA 98109

a 501(c)(3) nonprofit organization.

© Terms of Use & Privacy Policy